Gamida Cell price target raised to $25 from $13 at Piper Sandler Piper Sandler analyst Edward Tenthoff raised the firm's price target on Gamida Cell to $25 from $13 and keeps an Overweight rating on the shares. The analyst is citing the company's Phase 3 omidubicel data presented at the TCT Annual Meeting that showed "significantly lowered rate of serious infection" and reduced hospital stay. Tenthoff adds that along with less stringent HLA matching requirements, omidubicel can dramatically expand access and improve outcomes for HSCT patients, further stating that he is increasing his modeled value on omidubicel to $793M from $550M
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.